A prospective analysis of health-related quality of life in intermediate and high-risk prostate cancer patients managed with intensity modulated radiation therapy, with vs. without hormonal therapy

Caumont, Fernando; Conti, Galen; Hurwitz, Lauren M.; Kuo, Huai‐Ching; Levie, Katherine; Badiozamani, K.; Frankel, Jason; Flores, John Paul; Brand, Timothy C.; Chaurasia, Avinash; Rosner, Inger L.; Stroup, Sean P.; Musser, John E.; Cullen, Jennifer; Porter, Christopher R.

doi:10.1016/j.urolonc.2020.02.007

Cited by 4 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients who received hormone therapy, there was a worsening of sexual function, hormonal function, and hormonal bother. 33 Like Caumont et al, our study demonstrated the sexual and hormonal domains, with the most significant time-specific hormonal differences at 3 and 6 months. For patients with intermediate-risk prostate cancer, our study demonstrated that patients receiving proton beam RT and 6 months of ADT would have a return to baseline in sexual and hormonal domains in 6 months after the completion of treatment.…”

Section: Discussionsupporting

confidence: 77%

“…For patients with intermediate-risk prostate cancer, our study demonstrated that patients receiving proton beam RT and 6 months of ADT would have a return to baseline in sexual and hormonal domains in 6 months after the completion of treatment. Caumont et al 33 found no statistically significant differences in urinary function, urinary bother, sexual bother, bowel function, and bowel bother as part of the EPIC questionnaire. Similarly, we report that the addition of 6 months of ADT has no effect on GU or GI toxicity.…”

Section: Discussionmentioning

confidence: 96%

“…Multiple studies have examined the effect of ADT using different survey instruments. 33 In their prospective analysis, Caumont et al 33 compared patients with intermediate- and high-risk prostate cancer receiving RT alone versus RT plus ADT. The HRQoL scores were comparable in both groups.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003

Laughlin

Thorpe

DeWees

et al. 2023

Advances in Radiation Oncology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003

Laughlin

Thorpe

DeWees

et al. 2023

Advances in Radiation Oncology

View full text Add to dashboard Cite

“…Prostate cancer (PCa) is the third most common type of tumor in Europe, and the third most frequent cause of death from cancer in men [1]. Treatment selection is based on the disease risk category, the patient's age and comorbidities, the patient's preferences and the adverse effects profile of the treatment [2]. PCa is an androgen-dependent disease.…”

Section: Introductionmentioning

confidence: 99%

Interleukin-6 and Lymphocyte Count Associated and Predicted the Progression of Frailty Syndrome in Prostate Cancer Patients Undergoing Antiandrogen Therapy

Buigues

Navarro-Martínez

Sánchez-Martínez

et al. 2020

Cancers

View full text Add to dashboard Cite

Frailty syndrome is a functional state that includes a loss of ability to react to stressors, and is associated with poor outcomes, morbidity and premature mortality. The first line treatment in many men with prostate cancer (PCa) consists of an androgen-deprivation therapy (ADT) which can promote or favor frailty syndrome and ADT may therefore favor the progression of frailty over time. Among the pathophysiological bases of frailty, the presence of chronic low-grade inflammation has been associated with its adverse outcomes, but longitudinal studies are needed to validate these biomarkers. In this study, we prospectively evaluate frailty syndrome and blood inflammatory markers (IL1-beta, IL-6, IL-8, TNF alpha, C reactive protein) and leukocytes were measured at baseline and an average of 1 year later in PCa under ADT. Frailty was defined as having three or more of the following components: low lean mass, weakness, self-reported exhaustion, low activity level, and slow walking speed; prefrailty was defined as having one or two of those components. Multinomial regression analysis showed that among the inflammatory biomarkers, those significantly and repeatedly (baseline and follow-up time points) (p < 0.05) associated with frailty syndrome were high IL-6 levels and low lymphocyte counts in blood. Other biomarkers such as IL-8, monocyte counts and C reactive protein were significantly associated with frailty syndrome (p < 0.05) in cross-sectional analyses, but they do not predict frailty progression at 1 year-follow-up. Receiver operating characteristic curve analysis showed that both lymphocyte counts and IL-6 concentration significantly (p < 0.05) (although moderately) discriminate PCa patients that progressed in the severity of frailty syndrome. IL-6 and lymphocytes count are possible biomarkers, useful for identifying frail patients and predicting the progression of frailty in PCa under ADT. Our study suggests the use of these biomarkers to guide clinical decisions on prostate cancer treatment based on a multidisciplinary approach.

show abstract

Sexual Function and Quality of Life Among Turkish Oncology Patients Receiving Chemotherapy

Turhal

Koç

2023

Seminars in Oncology Nursing

View full text Add to dashboard Cite

A prospective analysis of health-related quality of life in intermediate and high-risk prostate cancer patients managed with intensity modulated radiation therapy, with vs. without hormonal therapy

Cited by 4 publications

References 19 publications

Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003

Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003

Interleukin-6 and Lymphocyte Count Associated and Predicted the Progression of Frailty Syndrome in Prostate Cancer Patients Undergoing Antiandrogen Therapy

Sexual Function and Quality of Life Among Turkish Oncology Patients Receiving Chemotherapy

Contact Info

Product

Resources

About